Prognostic value of advanced lung cancer inflammation index in head and neck squamous cell carcinoma

Jank, Bernhard J.; Kadletz, Lorenz; Schnoell, Julia; Perisanidis, Christos; Heiduschka, Gregor

doi:10.1007/s00405-019-05381-0

Cited by 21 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most noticeable finding of our present study was the first time successful exhibition of a vital incentive for the pre-C-CRT ALI in prognostic stratification of LA-NPC patients into two distinct groups treating the CSS, OS, PFS, and DMFS, but not LRPFS, results. Although it is difficult to dependably remark on the genuine value of these exceptional discoveries in absence of similarly designed ALI research, they seem to concur well with the published results of ALI studies for other tumor sites [ 12 – 17 , 25 ] and the NPC studies examining the prognostic utility of BMI, albumin, and NLR [ 6 – 8 ], namely, the components of ALI. Previously, Huang et al investigated the link between the pretreatment BMI and the clinical outcomes in patients with LA-NPC treated with C-CRT in a cohort of 400 patients [ 6 ].…”

Section: Discussionsupporting

confidence: 77%

“…Given such conclusive fundamental proof, multiple blood-borne biomarkers of the systemic inflammatory response, either each one seperately or in various blend forms, have been searched for their prognostic usefulness in patients with various cancers and disease stages, with published results harmoniously complimenting a solid connection between these markers and patients' prognoses irrespective of the disease stage [ 24 ]. As lately stated by Jafri et al, ALI represents one such unique blend that consolidates the BMI, albumin, and NLR, which demonstrated significant value in the prognostic lamination of patients presenting with various cancers [ 12 – 17 , 25 ]. Nevertheless, regardless of the convenience of dependable proof for the chronic inflammation either as a carcinogenesis initiator and/or as an accelerator of disease progression for NPCs, prompting the planning of our current study, ALI has never been studied before in LA-NPC patients managed with C-CRT for its prognostic merit.…”

Section: Discussionmentioning

confidence: 99%

“…Jafri et al exhibited strong prognostic worth for the advanced lung cancer inflammation index (ALI), as a novel prognostic system, for patients with metastatic non-small-cell lung cancer [ 12 ]. The prognostic merit of ALI was also addressed in succeeding esophageal cancer [ 13 ], small-cell lung cancer [ 14 ], diffuse large B-cell lymphomas [ 15 ], pancreatic cancer [ 16 ], and head and neck squamous cell cancer [ 17 ] investigations and was invariably reported to be an independent prognosticator in these tumor locales too. Interestingly, to date, the prognostic value of ALI has never been addressed in LA-NPC patients who were managed with concurrent chemoradiotherapy (C-CRT).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy

Topkan

Özdemir

Küçük

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

Purpose. We aimed to retrospectively investigate the prognostic worth of pretreatment advanced lung cancer inflammation index (ALI) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients treated with concurrent chemoradiotherapy (C-CRT). Patients and Methods. A total of 164 LA-NPC patients treated with cisplatinum-based definitive C-CRT were included in this retrospective cohort analysis. The convenience of ideal pre-C-CRT ALI cut-offs affecting survival results was searched by employing the receiver operating characteristic (ROC) curve analyses. The primary endpoint was the link between the ALI groups and overall survival (OS), while cancer-specific survival (CSS), locoregional progression-free survival [LR(PFS)], distant metastasis-free survival (DMFS), and PFS comprised the secondary endpoints. Results. The ROC curve analyses distinguished a rounded ALI cut-off score of 24.2 that arranged the patients into two cohorts [ALI ≥ 24.2 (N = 94) versus < 24.2 (N = 70)] with significantly distinct CSS, OS, DMFS, and PFS outcomes, except for the LRPFS. At a median follow-up time of 79.2 months (range: 6–141), the comparative analyses showed that ALI < 24.2 cohort had significantly shorter median CSS, OS, DMFS, and PFS time than the ALI ≥ 24.2 cohort ( P < 0.001 for each), which retained significance at 5- ( P < 0.001 ) and 10-year ( P < 0.001 ) time points. In multivariate analyses, ALI < 24.2 was asserted to be an independent predictor of the worse prognosis for each endpoint ( P < 0.001 for each) in addition to the tumor stage (T-stage) ( P < 0.05 for all endpoints) and nodal stage (N-stage) ( P < 0.05 for all endpoints). Conclusion. As a novel prognostic index, the pretreatment ALI < 24.2 appeared to be strongly associated with significantly diminished survival outcomes in LA-NPC patients treated with C-CRT independent of the universally recognized T- and N-stages.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy

Topkan

Özdemir

Küçük

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…1. Ultimately, nine studies met our selection criteria; after excluding duplicated studies and reviewing the full texts of the manuscripts [25,[29][30][31][32][33][34][35][36], a total of 1736 cases were included. With respect to prognostic outcomes, nine studies reported OS, two studies reported progression-free survival, and one study reported disease-free survival.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Hua

Chen

et al. 2019

World J Surg Onc

View full text Add to dashboard Cite

Background: Inflammation plays a critical role in the development and progression of cancers. The advanced lung cancer inflammation index (ALI) is thought to be able to reflect systemic inflammation better than current biomarkers. However, the prognostic significance of the ALI in various types of cancer remains unclear. Our metaanalysis aimed to comprehensively investigate the relationship between the ALI and oncologic outcomes to help physicians better assess the prognosis of cancer patients. Methods: The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases were searched for relevant studies. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated and pooled from the included studies. Furthermore, a sensitivity analysis was performed to evaluate the reliability of the articles. Finally, Begg's test, Egger's test, and the funnel plot were applied to assess the significance of publication bias. Results: In total, 1736 patients from nine studies were included in our meta-analysis. The median cutoff value for the ALI was 23.2 (range, 15.5-37.66) in the analyzed studies. The meta-analysis showed that there was a statistically significant relationship between a low ALI and worse overall survival (OS) in various types of cancer (HR = 1.70, 95% CI = 1.41-1.99, P < 0.001). Moreover, results from subgroup meta-analysis showed that the ALI had a significant prognostic value in non-small cell lung cancer, small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and diffuse large B cell lymphoma (P < 0.05 for all). Conclusions: These results showed that a low ALI was associated with poor OS in various types of cancer, and the ALI could act as an effective prognostic biomarker in cancer patients.

show abstract

“…Neutrophilia and increased neutrophil-to-lymphocyte ratios (NLR) are markers of inflammation and are shown to be associated with decreased overall survival in HNSCC [14][15][16]. Furthermore, high expression of downstream inflammatory cytokines is associated with worse overall survival in HNSCC [17,18].…”

Section: Introductionmentioning

confidence: 99%

MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Radiation therapy (RT) is a cornerstone of treatment in the management of head and neck squamous cell carcinomas (HNSCC), yet treatment failure and disease recurrence are common. The p38/MK2 pathway is activated in response to cellular stressors, including radiation, and promotes tumor inflammation in a variety of cancers. We investigated MK2 pathway activation in Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:

show abstract

Prognostic value of advanced lung cancer inflammation index in head and neck squamous cell carcinoma

Cited by 21 publications

References 25 publications

Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy

Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy

Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma

Contact Info

Product

Resources

About